Latest research on Celecoxib

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.

Celecoxib and alcohol

Information was collected through researcher by a questionnaire including demographic characteristics, the history of smoking (smoking more than 10 cigarette per day for at least one year), alcohol consumption (with DSM-IV-TR criteria, and alcoholic products with daily consumption including beer, vodka, whisky, wine, fortified wine and hard liquor), NSAIDs usage and the type of consumed drugs (low dose daily Aspirin, or other drugs including Naproxen, Indomethacin, Ibuprofen, Diclofenac Na , Piroxicam, and Mefenamic Acid except Celecoxib), use of multiple NSAIDs, length of time taking NSAIDs, vital signs and hemoglobin level ( on their arrival, patient’s hemoglobin test was carried out using chromatography by BT devices), clinical manifestation in patients within early hours of admission, clinical features of disease and finally endoscopic findings in patients. [source, 2013]
Several compounds such as difluoromethylornithine (an inhibitor of polyamine synthesis) and perillyl alcohol (a monoterpene) are already in phase I-II prevention testing, and trials for others such as Celecoxib, a COX-2 inhibitor, and ZD1839, a TYROSINE kinase inhibitor, are in the active planning stage [32,33,34,35]. [source, 2001]
In a specific experiment, the mice were either treated or not treated with MK886 (5-LO inhibitor, 5 mg kg−1 i.p., in 200 μl of 1% alcohol in water)64, Indomethacin (COX1/2 inhibitor, 2 mg kg−1 i.p. in 200 μl of Tris[hydroxymethyl]aminomethane-HCl; TRIS-HCl, pH 8.2)65, SC-560 (selective COX1 inhibitor, 3 mg kg−1 i.p., in 200 μl of PBS, Sigma-Aldrich)66, Celecoxib (COX2 inhibitor, 5 mg kg−1 i.p., in 200 μl of water)64 or EP2 antagonist (AH6809, 5 mg kg−1 i.p., in 200 μl of PBS, Cayman Chemical)67. [source, 2016]